Dose-dependent induction of the PLS poor-prognosis status by Ang I and Ang II demonstrates the functional activity of ACE and AGTR1 in the cPLS model, as well as the impact of the pathway activation in the modulation of the PLS associated with HCC risk (Figure 1E and Supplemental Table 2). The gene discussed is AGT; the disease is hepatocellular carcinoma.